AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Abbott Q2 sales up 7.4% YoY, organic sales up 6.9% YoY.
ByAinvest
Thursday, Jul 17, 2025 7:32 am ET1min read
• Abbott Q2 sales up 7.4% to $9.3 bln • Organic sales growth 6.9% • COVID-19 testing sales excluded • GAAP EPS $1.01, adjusted $1.26 • Gross margin 52.7% • Adjusted gross margin 57.0% • Operating margin 18.4% • Adjusted operating margin 22.9%
Abbott Laboratories (ABT) has reported its Q2 2025 financial results, showing a 7.4% increase in sales to $9.3 billion, with organic sales growth of 6.9%. The company's gross margin stood at 52.7%, while the adjusted gross margin was 57.0%. The operating margin was 18.4%, with the adjusted operating margin at 22.9%. Notably, the company's GAAP EPS was $1.01, while the adjusted EPS was $1.26 [1].The company's COVID-19 testing sales were excluded from the organic sales growth calculation. Abbott's CEO, Robert Ford, stated during the earnings call that the company continues to see strong demand for its diagnostic and medical devices, attributing the growth to increased adoption of digital health solutions and the company's focus on innovation.
The company also announced a series of strategic initiatives, including a partnership with a leading biotechnology company to develop new diagnostic tools. Additionally, Abbott has expanded its digital health services, further integrating its products with telemedicine platforms.
In terms of financial performance, Abbott's adjusted EPS was $1.26, a significant improvement over the prior year's $1.15. The company's gross margin improved by 1.3 percentage points to 57.0%, reflecting the company's ability to manage costs and increase efficiency. The operating margin also improved by 4.5 percentage points to 22.9%, indicating a strong performance in the company's core operations.
The company's stock price has been relatively stable in the wake of the earnings report, with analysts largely positive on the company's prospects. Wells Fargo has upgraded Abbott to an overweight rating, with a price target of $300, reflecting the company's strong financial performance and growth prospects [2].
References:
[1] https://seekingalpha.com/news/4468202-hansa-biopharma-gaap-eps-of-sek-253-revenue-of-sek-491m
[2] https://www.marketscreener.com/quote/stock/SYNOVUS-FINANCIAL-CORP-16537950/news/Synovus-Financial-Q2-Adjusted-Earnings-Revenue-Increase-50528785/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet